Silence Therapeutics

NASDAQ: SLN · Real-Time Price · USD
5.48
-0.15 (-2.66%)
At close: Aug 15, 2025, 3:59 PM
5.49
0.09%
After-hours: Aug 15, 2025, 04:10 PM EDT

Silence Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
142K 24.33M 1.14M 598K 12.41M 2.1M 2.8M 9.1M 11.37M 4.76M 3.37M 3.64M 5.72M 3.41M 3.16M 2.7M 3.14M
Cost of Revenue
54K 1.61M 2.77M 2.64M 2.21M 1.35M 1.61M 2.83M 4.53M 3.86M 2.39M 2.35M 2.27M 2.04M 2.05M 1.82M 1.54M
Gross Profit
88K 22.72M -1.63M -2.04M 10.19M 753K 1.19M 6.27M 6.84M 906K 977K 1.29M 3.45M 1.37M 1.1M 876K 1.61M
Operating Income
-28.41M -3.08M -22.54M -18.32M -4.16M -13.3M -12.7M -11.46M -12.15M -10.96M -13.62M -14.09M -9.92M -11.26M -12.28M -12.93M -9.34M
Interest Income
n/a 886.95K 981K 1.06M 804K n/a 2.05M 340K 336K 10K 4.33M 669K 350K 2K 296K 219K 2K
Pretax Income
-28.53M 23.74M -30.16M -17.44M -3.37M -14.97M -10.66M -12.01M -12.67M -15.05M -9.33M -13.42M -9.57M -11.23M -12.05M -12.71M -9.87M
Net Income
-28.53M 14.17M -27.01M -15.56M -1.88M -14.41M -8.25M -10.4M -10.2M -13.76M -7.1M -11.94M -7.68M -9.43M -9.93M -11.63M -8.42M
Selling & General & Admin
7.68M 5.4M 5.6M 5.29M 5.17M 4.12M 4.96M 5.12M 6.45M 3.47M 5.83M 4.55M 5.77M 5.41M 5.47M 5.38M 3.75M
Research & Development
20.81M 20.4M 15.3M 10.99M 9.18M 9.94M 8.93M 12.62M 12.54M 8.4M 8.77M 10.83M 7.6M 7.22M 7.92M 8.17M 7.46M
Other Expenses
n/a -0.00 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 259K -259K
Operating Expenses
28.5M 25.8M 20.91M 16.28M 14.35M 14.05M 13.89M 17.73M 18.99M 11.87M 14.6M 15.38M 13.37M 12.63M 13.39M 13.8M 10.95M
Interest Expense
n/a -11.54M 8.6M 183K 13K 928K 8K 893K 860K n/a 34K n/a n/a n/a 64K n/a 531K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
28.55M 27.41M 23.68M 18.92M 16.56M 15.4M 15.5M 20.56M 23.52M 15.73M 16.99M 17.73M 15.64M 14.68M 15.44M 15.63M 12.48M
Income Tax Expense
n/a 9.56M -3.15M -1.88M -1.49M -554K -2.41M -1.61M -2.47M -1.29M -2.22M -1.48M -1.89M -1.79M -2.12M -1.08M -1.45M
Shares Outstanding (Basic)
47.23M 47.22M 46.74M 46.74M 43.96M 38.92M 37.31M 36.16M 35.98M 32.19M 32.91M 29.93M 29.93M 29.65M 29.91M 29.89M 28.85M
Shares Outstanding (Diluted)
47.23M 47.22M 46.74M 46.74M 43.96M 38.92M 37.31M 36.16M 35.98M 32.19M 32.91M 29.93M 29.93M 29.65M 29.91M 29.89M 28.85M
EPS (Basic)
-0.6 0.31 -0.57 -0.33 -0.04 -0.36 -0.22 -0.29 -0.28 -0.42 -0.22 -0.39 -0.26 -0.33 -0.33 -0.39 -0.29
EPS (Diluted)
-0.6 0.31 -0.57 -0.33 -0.04 -0.36 -0.22 -0.29 -0.28 -0.42 -0.22 -0.39 -0.26 -0.33 -0.33 -0.39 -0.29
EBITDA
-28.41M 7.19M -21.44M -17.14M -4.04M -14.91M -10.53M -11M -11.68M -10.88M -9.18M -13.31M -9.46M -11.2M -11.88M -12.59M -9.21M
EBIT
-25.73M 7.07M -21.56M -17.26M -3.35M -15.03M -10.65M -11.12M -11.81M -15.04M -9.29M -13.42M -9.57M -11.3M -11.99M -12.71M -9.34M
Depreciation & Amortization
138K 119.28K 115K 119K 120K 121K 125K 118K 134K 141K 114K 114K 113K 66K 110K 123K 128K